Last updated: February 16, 2026
Product Overview
NDC 00781-3113 corresponds to Tafamidis meglumine, marketed as Vyndaqel and Vyndamax by Pfizer. It is approved for transthyretin amyloid cardiomyopathy (ATTR-CM). The drug addresses a rare, life-threatening disease with limited treatment options, positioning it within the orphan drug market segment.
Market Size and Adoption
Target Population: The prevalence of ATTR-CM is estimated at 1-4 per 100,000 in the general population, with higher rates in older adults. Recent studies suggest a significant underdiagnosis, with some estimates indicating millions potentially affected globally. In the U.S., approximately 250,000 patients may be eligible based on disease prevalence and diagnosis rates.
Market Penetration: As of 2022, Pfizer’s market penetration remains below full capacity owing to diagnostic challenges and limited physician awareness. Adoption varies across regions, with higher rates in developed markets due to better diagnostic infrastructure.
Competitive Landscape: The primary competitor is Alnylam’s Onpattro (patisiran), approved for hereditary ATTR amyloidosis with polyneuropathy but not cardiomyopathy. Eli Lilly’s therapies are under development. No direct generic equivalents are available, maintaining high brand exclusivity.
Sales and Revenue Trends
Historical Data (2020–2022): Pfizer reported global sales exceeding $1.3 billion in 2022. Sales growth averaged approximately 20% annually, driven primarily by increased uptake in the U.S. and expanding indications.
Sales Drivers: Expanded insurance coverage, physician education, and diagnosis rates have increased prescriptions. The drug’s orphan status supports premium pricing and long-term exclusivity until at least 2030.
Pricing Analysis
Current Pricing (2023): The average wholesale price (AWP) for Vyndaqel and Vyndamax ranges from $24,000 to $30,000 per year per patient. Actual negotiated prices with payers are lower, with average net prices estimated around $15,000 to $20,000 annually.
Comparison: The pricing is comparable or higher than other monoclonal antibody or specialty drugs for rare diseases, reflecting the orphan drug premium. The lack of generic competition sustains high list prices.
Cost-Effectiveness: Health economic assessments, such as quality-adjusted life years (QALYs), support the current pricing structure due to the severe progression of ATTR-CM and lack of alternatives.
Price Projections
Short-term (Next 2 Years): With increasing diagnosis rates and expanded indications, sales are projected to grow 10-15% annually. List prices are unlikely to decrease significantly unless regulatory or patent changes occur.
Medium-term (3-5 Years): Patent exclusivity persists until at least 2030. No significant generic or biosimilar competition is expected before then, maintaining high prices. Payer negotiations may influence net prices, but list prices remain stable.
Long-term (Beyond 5 Years): Patent expiration or reformulated versions could lead to price erosion. However, given the orphan status and limited competition, price declines are expected to be moderate unless biosimilar entries or alternative therapies gain approval.
Regulatory and Policy Influences
Changes in healthcare policies, such as pricing reforms or increased pressure for biosimilar adoption, can influence pricing. The U.S. Inflation Reduction Act and similar policies in other regions may impact net prices or reimbursement strategies over the next decade.
Implications for Stakeholders
- Pharmaceutical Companies: Significant revenue potential persists due to high unmet needs and limited competition.
- Healthcare Systems: High drug costs challenge budget allocations, emphasizing the importance of negotiated discounts.
- Investors: The product’s revenue stability supports the valuation of Pfizer’s specialized drug portfolio, with growth prospects hinging on diagnosis expansion and regulatory acceptance.
Key Takeaways
- NDC 00781-3113 (Tafamidis meglumine) generates approximately $1.3 billion in annual revenue.
- The high price point is maintained by orphan drug status and limited competition.
- Sales are projected to grow 10-15% annually over the next two years, with stable list prices.
- Patent protections until at least 2030 prevent significant price erosion.
- Market expansion depends on improved diagnosis and indication approvals.
FAQs
-
What factors could lead to price reductions for tafamidis?
Patent expiration, regulatory approval of biosimilars, broader indications, or healthcare policy reforms could lower prices.
-
How does diagnostic rate impact market outlook?
Enhanced diagnosis increases eligible patient numbers, driving sales upward and supporting sustained pricing.
-
Are there any upcoming competitors?
No direct competing drugs are approved yet. Several candidates are in clinical trials but face regulatory and development hurdles.
-
What is the impact of reimbursement policies on net prices?
Reimbursement negotiations and formulary placements can lower net prices, though list prices tend to remain stable.
-
Could biosimilar entry threaten existing pricing?
Potential biosimilar development targeting tafamidis exists but faces scientific and regulatory challenges that delay their market entry.
Citations:
[1] Pfizer. Vyndaqel and Vyndamax product information. 2023.
[2] IQVIA. Specialty drug sales and market data, 2022.
[3] Global Data. ATTR-CM epidemiology and diagnosis reports, 2022.
[4] FDA. Drug approval and patent status, 2022.
[5] Health Economics and Outcomes Research, Pricing Reports 2023.
